Healthcare Industry Media Coverage2017-09-13T20:18:16+00:00

Media Coverage

AbbVie Prompts Patients to ‘take on’ Arthritis in First Rinvoq DTC Ad

From: FiercePharma By: Beth Snyder Bulik           AbbVie Prompts Patients to 'take on' Arthritis in First Rinvoq DTC Ad While Xeljanz still enjoys support from rheums given the drug’s seven-year commercial history, docs indicated Rinvoq as the most preferred JAK if only one were to be prescribed, citing safety, efficacy and breadth of data all as key advantages over Xeljanz," Piper Jaffray analyst Christopher Raymond wrote...(read more).

March 2, 2020|

Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS

From: Multiple Sclerosis News Today By: Ana Pena, PHD. Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS First-line use of Genentech's Ocrevus (ocrelizumab) for patients with multiple sclerosis (MS) has remained stable through 2019 compared to 2018, according to the latest Spherix Global Insights' report...(read more).

February 14, 2020|

AbbVie’s Rinvoq continues march with NICE nod in rheumatoid arthritis

From: FiercePharma By: Kyle Blankenship           AbbVie's Rinvoq Continues March with NICE Nod in Rheumatoid Arthritis In December, a rheumatologist survey conducted by Spherix Global Insights showed about half of 100 physicians would prescribe Rinvoq over other JAK inhibitors, specifically citing AbbVie's "stewardship" of the drug as a positive for prescribing, Piper analyst Christopher Raymond said in a note to investors...(read more).

January 31, 2020|

Lilly Launches Real-World Study to Benchmark Emgality Against Migraine Rivals

From: Fierce Pharma By: Eric Sagonowsky           Lilly Launches Real-World Study to Benchmark Emgality Against Migraine Rivals Eli Lilly’s CGRP migraine prevention med Emgality trailed its rivals onto the market, but it’s been a force in the dogfight for market share. Now, in an effort to learn more about how physicians choose between the med and its competitors, the company has started a real-world evidence study...(read more).

December 18, 2019|

Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst

From: FiercePharma By: Kyle Blankenship           Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst Between AbbVie's two newly approved blockbusters-in-waiting, psoriasis med Skyrizi's booming sales have drawn some analysts' eyes away from highly-touted rheumatoid arthritis drug Rinvoq. But among physicians, Rinvoq is becoming a darling, one analyst says––and an "AbbVie halo" could be major part of that...(read more).

December 4, 2019|

Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says

From: Multiple Sclerosis News Today By: Ana Pena, PHD       Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says Genentech‘s Ocrevus (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosis (SPMS) among U.S. neurologists, even though Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) were approved in March to treat this same MS group, according to a 2019 report by Spherix Global Insights...(read more).

November 22, 2019|